PARP Inhibitors for Ovarian Cancer: The Side Effects
- The most common side effects of PARP inhibitors are nausea, vomiting, and fatigue.
- Reducing the dosage can lessen side effects without impacting efficacy if needed.
- After the first month, many patients will adapt to these drugs and the side effects can subside, or become easier to tolerate.
Most recently, the American Society of Clinical Oncology (ASCO) released new guidelines recommending PARP inhibitors be offered to women, with or without genetic mutations, who are newly diagnosed with stage III or IV ovarian cancer and have improved with chemotherapy.
Read MoreAnother common complaint that Geller hears is that patients are often very fatigued. Some of that, she says, can be due to low hemoglobin levels. "We watch that very carefully. Most of our patients who are on PARP inhibitors get blood testing every month. Even if we don’t bring them in to be seen, we're still monitoring their blood levels. Occasionally, a patient may require a transfusion, though that's pretty rare."
When doctors do see counts start to drop, they might reduce the dosage of the PARP inhibitors to help alleviate the anemia and the fatigue. "Most patients see an improvement once we make that dose adjustment,” Geller says, though occasionally doctors may have to switch to a different PARP inhibitor for a patient to feel noticeably better.
"After that first month, most patients, for whatever reason, start to get used to the medication and do much better on it." The fatigue especially tends to pass, or else it’s lessened to where it’s no longer an issue.
Dr. Amanika Kumar of the Mayo Clinic who spoke to SurvivorNet, cautioned that women still need to speak with their doctor to evaluate the benefit of taking a PARP inhibitor to extend life, because there are very real side effects due to the toxicity of the drug. "Patients with HRD (homologous recombination deficiency) have a far better response than those without and those with BRCA mutations even more so. It is on us as clinicians to help patients understand the risks and benefits of treatment. Patients that have no mutation or HRD may choose not to go on maintenance (in fact I recommend they don't) because there is real toxicity to these meds."
Learn more about SurvivorNet's rigorous medical review process.